Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06618027

Pragmatic Clinic-Based Trial of a Mindfulness Based Intervention for Mood Concerns in Youth With Type 1 Diabetes

Type 1 diabetes (T1D) is a common chronic illness among children requiring a high degree of self-management for good glycemic control. Adolescents are at risk for poor disease management and health outcomes due to a number of factors, including high rates of depression, anxiety, and stress. Accessing support for these challenges can be a barrier to care, so the current study, BRinging Empowerment and Attention to Teen HEalth-T1D, evaluates the efficacy of a virtual, group-based mindfulness based intervention and a virtual group-based diabetes education intervention on improving symptoms of depression and anxiety, and diabetes self management in teens with T1D. The study also aims to study how these interventions might be implemented in diabetes clinic settings.

Recruiting

Interested in participating?

Request Info

Key information

Age range

13 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Barbara Davis Center, Aurora, Colorado, United States

Loading trial locations.

About this study

Type 1 diabetes (T1D) is one of the most common chronic illnesses of childhood affecting around 200,000 youth in the US. Youth with T1D are at heightened risk for serious adverse health consequences as compared to their peers without T1D, but treatment adherence markedly reduces this risk. Adolescence is a critical period for determining the course of T1D as treatment adherence and glycemic target achievements deteriorate in adolescence, with ~80% failing to meet glycemic targets. Adolescents' failure to adhere to standards of treatment can result in poor glycemic control (HbA1c >7.0%), which if unaddressed, increases the risk of serious adverse health consequences. Effective intervention to address glycemic control in adolescents with T1D remains elusive. Negative affect-including depression and anxiety-increases during adolescence and is a key contributor to treatment non-adherence and glycemic control above targets. As many as 40% of adolescents with T1D have elevated depression and anxiety symptoms, which likely impact adherence and glycemia through stress-related behavior (e.g., disordered eating, avoidant coping). Trials of effective interventions to decrease negative affect and downstream, stress-related behaviors are critical to improve the health of adolescents with T1D.

Our pilot study adapted a brief group mindfulness-based intervention (MBI) for teens with T1D utilizing stakeholder input and designed with an iterative approach (BREATHE-T1D). Our R34 demonstrated that BREATHE-T1D was highly feasible (100% of eligible teens approached enrolled with a 93% retention rate) and demonstrated outstanding acceptability, with teens participating in 98% of sessions and reporting high value of participation. Those randomized to BREATHE-T1D had evidence of more clinical improvement for depression and HbA1c while those in the health education comparison had stability or worsening of symptoms. Improvements over time were seen in anxiety, diabetes distress, and disordered eating for participants. Existing data from randomized controlled trials (RCT) support the efficacy of MBI for decreasing negative affect and stress-related behavior in adolescents without T1D. The next step is to evaluate the efficacy of BREATHE-T1D in a 2-site study as compared to our health education attention control (HealthEd-T1D). In our R34, providers noted that many adolescents have psychosocial concerns, yet there are grossly inadequate referral sources and a need for integration of efficacious programs into clinic settings. Therefore, it is critical to design interventions for implementation and sustainability and evaluate how the intervention is aligned with infrastructure in real world settings.

The current study is a partnership with Children's National and the University of Colorado to conduct an RCT comparing BREATHE-T1D and HealthEd-T1D in N=200 adolescents 13-17y with >1 year duration of T1D and elevated negative affect. This study is a pragmatic trial to evaluate the efficacy of BREATHE-T1D and methods of implementation of this program into the clinic setting for which it is designed. Given the positive response to the pilot trial, the value of evaluating screening and referral in clinic, increased emphasis on in-clinic screening for mood, anxiety, and disordered eating, and evaluating outcomes relevant to the clinic setting enables both evaluation of efficacy as well as feasibility of clinic implementation. The intervention will be conducted virtually and the trial will employ multi-method assessment of outcomes including self-report, parent-report, and indica-tors of diabetes management (i.e., blood glucose variability via Continuous Glucose Monitors or blood glucose meters and glycemic control via HbA1c). N=200 adolescents will be randomized 1:1 to BREATHE-T1D or HealthEd-T1D and have a baseline assessment, 7 weeks of groups, and follow-ups 3 months and 1 year following baseline.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type 1 diabetes diagnosed for at least 1 year
  • Elevated score on depression measure OR elevated score on anxiety measure

Exclusion criteria

  • Cognitive or developmental delays that restrict ability to complete study interventions or assessments
  • Teen not fluent in English
  • No other serious medical conditions (e.g., cystic fibrosis, cancer)

Treatment and study plan

BREATHE-T1D

Behavioral

BREATHE-T1D was adapted from Learning to BREATHE, a group mindfulness-based intervention for teens. It teaches mindfulness strategies adapted to be specific and relatable to, teens with T1D to improves symptoms of depression and anxiety as well as diabetes self-management.

HealthEd-T1D

Behavioral

HealthEd-T1D is a 6 week, virtual, group based diabetes education group.

Primary outcomes

  1. Glycemic control

    Time frame: Baseline, 3-, and 12-months post intervention

    Glycemic control will be measured by at home hemoglobin A1c kits as well as downloads of continuous glucose monitor or blood glucose meter data across a 2 week period, with percent of time in range (70-180) calculated and HbA1c used as an indicator of glycemic control over the prior 3 months.

  2. Depression

    Time frame: Baseline, 3-, and 12-months post intervention

    Center for Epidemiologic Studies Depression Scale (CES-D). The CES-D is a self-report scale on symptoms of depression experienced over the prior two weeks. The possible range of scores is 0-60 with higher scores indicating more severe symptoms of depression.

Secondary outcomes

  1. Anxiety

    Time frame: Baseline, 3-, and 12-months post intervention

    Screen for Child Anxiety Related Disorders (SCARED). The SCARED is a self report measure with higher scores indicative of an anxiety disorder.

  2. Disordered Eating

    Time frame: Baseline, 3-, and 12-months post intervention

    Diabetes Eating Problem Survey - Revised (DEPS-R) is a self-report measure that asks about disordered eating behaviors, including those specific to individuals with diabetes. Higher scores indicate more disordered eating symptoms.

  3. Mindfulness

    Time frame: Baseline, 3-, and 12-months post intervention

    Mindful Attention Awareness Scale (MAAS) is a self-report measure assessing how mindful people are in their day to day lives. Higher scores indicate higher levels of dispositional mindfulness.

  4. Mindfulness

    Time frame: Baseline, 3-, and 12- months

    The Five-Factor Mindfulness Questionnaire is a self-report measure that evaluates elements of mindfulness, including the following aspects: observing, describing, acting with awareness, nonreactivity, and non-judgement. Higher scores indicate a higher level of mindfulness.

  5. Stress

    Time frame: Baseline, 3-, and 12-months post intervention

    PROMIS Stress Scale is a brief self-report measure that asks about experiences of stress over the past 2 weeks. Higher scores indicate more experiences of stress.

  6. Executive Functioning

    Time frame: Baseline, 3-, and 12-months post intervention

    Parent report Behavior Rating Inventory of Executive Function (BRIEF). The BRIEF uses parent report of adolescent executive function, or the ability to plan, organize, and other aspects of executive function. Higher scores indicate the presence of executive functioning challenges.

  7. Negative Urgency

    Time frame: Baseline, 3-, and 12-months post intervention

    UPPS-P Negative Urgency scale is a self-report scale which assesses impulsive behavior, particularly when experiencing negative mood. Higher scores indicate greater challenge with acting impulsively when upset.

  8. Avoidant Coping

    Time frame: Baseline, 3-, and 12-months post intervention

    Responses to Stress Questionnaire - Diabetes (RSQ-D). The Responses to Stress Questionnaire is a self- and parent- reported measure assessing presence of stressors, some of which are specific to having diabetes, and what coping strategies are used to manage these. Higher scores indicate more use of various coping strategies.

  9. Diabetes Distress

    Time frame: Baseline, 3-, and 12-months post intervention

    Problem Areas in Diabetes Scale - Teen (PAID-T). The PAID-T is a self-report measure that assesses a teen's perspective on how much distress they experience as a result of having or managing type 1 diabetes. HIgher scores indicate greater levels of diabetes-related distress.

  10. Diabetes Self-Management

    Time frame: Baseline, 3-, and 12-months post intervention

    Self Care Inventory (SCI). The SCI is a self-report measure on how much the teen adheres to medical recommendations to self-manage their diabetes. Higher scores indicate the presence of more self-management behaviors.

Study contacts

Contact information is provided by the study sponsor or research team.

Eleanor Mackey, PhD

CONTACT

[email protected]

202-476-5307

Sponsors and collaborators

Lead sponsor

Children's National Research Institute

Other

Collaborators

  • Barbara Davis Center of Childhood Diabetes, University of Co
  • Colorado State University
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registry information

Acronym: BREATHE-T1D

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
Oct 1, 2024
Registry last updated
Jul 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.